| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $669K | — | -87.5% |
| SG&A Expense | $5.3M | — | -41.3% |
| Operating Income | -$7.0M | — | +77.1% |
| Net Income | -$4.2M | — | +85.1% |
| EPS (Basic) | -$0.62 | — | +85.6% |
| EPS (Diluted) | -$0.62 | — | +85.6% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $5.0M | -24.3% | -67.3% |
| Current Assets | $188.3M | -1.6% | -14.1% |
| Total Assets | $200.4M | -1.5% | -15.6% |
| Current Liabilities | $4.7M | -2.5% | -34.7% |
| Total Liabilities | $89.7M | +0.1% | -3.0% |
| Stockholders' Equity | $110.7M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.3M | — | +68.1% |
| Investing Cash Flow | -$317K | — | -103.3% |
| Financing Cash Flow | $0 | — | -100.0% |
| -23.6% |